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Abstract
Background: In 2002, home-based management of fever (HBMF) was introduced in Uganda, to improve access to
prompt, effective antimalarial treatment of all fevers in children under 5 years. Implementation is through community
drug distributors (CDDs) who distribute pre-packaged chloroquine plus sulfadoxine-pyrimethamine (HOMAPAK®) free
of charge to caretakers of febrile children. Adherence of caretakers to this regimen has not been studied.
Methods: A questionnaire-based survey combined with inspection of blister packaging was conducted to investigate
caretakers' adherence to HOMAPAK®. The population surveyed consisted of internally displaced people (IDPs) from
eight camps.
Results: A total of 241 caretakers were interviewed. 95.0% (CI: 93.3% – 98.4%) of their children had received the
correct dose for their age and 52.3% of caretakers had retained the blister pack. Assuming correct self-reporting, the
overall adherence was 96.3% (CI: 93.9% – 98.7%). The nine caretakers who had not adhered had done so because the
child had improved, had vomited, did not like the taste of the tablets, or because they forgot to administer the treatment.
For 85.5% of cases treatment had been sought within 24 hours. Blister packaging was considered useful by virtually all
respondents, mainly because it kept the drugs clean and dry. Information provided on, and inside, the package was of
limited use, because most respondents were illiterate. However, CDDs had often told caretakers how to administer the
treatment. For 39.4% of respondents consultation with the CDD was their reported first action when their child has
fever and 52.7% stated that they consult her/him if the child does not get better.
Conclusion: In IDP camps, the HBMF strategy forms an important component of medical care for young children. In
case of febrile illness, most caretakers obtain prompt and adequate antimalarial treatment, and adhere to it. A large
proportion of malaria episodes are thus likely to be treated before complications can arise. Implementation in the IDP
camps now needs to focus on improving monitoring, supervision and general support to CDDs, as well as on targeting
them and caretakers with educational messages. The national treatment policy for uncomplicated malaria has recently
been changed to artemether-lumefantrine. Discussions on a suitable replacement combination for HBMF are well
advanced, and have raised new questions about adherence.
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Background
Prompt and effective treatment of malaria remains a chal-
lenge for malaria control programmes. From the moment
a patient experiences the first symptoms of malaria to the
point when the disease has been cured, many potential
barriers have to be overcome. These include delays in rec-
ognition of symptoms and treatment seeking, and non-
adherence to the drug regimen. Helping caretakers of
young children to overcome these and other barriers to
prompt and effective treatment is of particular importance
in sub-Saharan Africa. In this malaria endemic region,
severe malaria is the most common cause of death of
young children. The greatest proportion of these deaths is
due to the lack of early recognition of malaria symptoms
(which overlap with those of other fatal febrile illnesses in
early childhood) and their management with prompt and
effective treatment within 24 hours of onset of symptoms
[1-5].
In most of the highly malaria endemic areas of sub-Saha-
ran Africa, malaria is initially treated at home with drugs
purchased from the private sector [6-9]. Uganda was no
exception to this prior to 2002 [10-12], which is when the
Ministry of Health (MoH) introduced the Home Based
Management of Fever (HBMF) strategy [13]. HBMF is
based on the Home Based Management of Malaria strat-
egy developed by Roll Back Malaria [14,15]. The key com-
ponents are: i) effective communication to enable
caretakers to recognise malaria illness early and to take
appropriate action, ii) ensuring that Community Drug
Distributors (CDDs) and health service providers have the
skills to manage malaria illness, iii) ensuring availability
and access to effective and preferably pre-packaged anti-
malarial drugs, and iv) providing a mechanism for super-
vision and monitoring. The potential for HBMF to reduce
under-five mortality and progression to severe malaria is
enormous [16,17].
Three years after its introduction in Uganda HBMF covers
almost the whole country, though it is at various stages of
implementation. The current treatment of choice is a pre-
packaged combination of sulfadoxine-pyrimethamine
(SP) and chloroquine (CQ) with the trade name
HOMAPAK®, though it has recently been decided to
change it. Discussions on a suitable replacement combi-
nation are well advanced. Distribution relies on volunteer
CDDs that are trained and provided with a supply of
HOMAPAK®. Monitoring and supervision of this activity
is the responsibility of the nearest health facility.
Evaluations have been carried out in a number of districts
[18,19], but none have attempted to examine adherence
to the drug regimen. Building on previous support of the
Malaria Consortium to the HBMF implementation in the
northern districts of Gulu, Kitgum and Pader [20], the
present work was carried out to study the adherence to
HOMAPAK® in caretakers of children among internally
displaced persons (IDP) in this region. The results are
meant to contribute to the evidence-base of HBMF in
Uganda, allowing for adjustment of the strategy where
necessary.
Methods
Study area
The study was conducted in Gulu district in the northwest
of Uganda. The district comprises five sub-districts, Aswa,
Kilak, Omoro, Gulu and Nwoya. The centre is the town of
Gulu. The region is inhabited by the Acholi tribe, which
speaks a local language called Luo.
Gulu and the neighbouring districts of Kitgum and Pader
have suffered from 18 years of conflict caused by the activ-
ities of a rebel group, the Lord's Resistance Army (LRA).
Activities are directed against the central government, but
often target the civilian population [21]. As a result, more
than two million people have been displaced and are now
living in camps for internally displaced persons (IDPs).
Most camps were established next to the bases of the
Uganda's People Defence Force (i.e. the national army)
and houses are grouped very closely together, to provide
better protection from LRA attacks. This has resulted in
over-crowded living conditions.
Recent data for Gulu district shows that there are presently
460,000 IDPs living in 53 recognised camps [22]. The
older, better-established camps have a health unit and
trained community owned resource persons (CORPs).
Inhabitants of more recently established camps are gener-
ally required to travel to the nearest camp with a health
unit for medical assistance or to consult a CORP trained
in health, where available. A number of different cadres of
CORPs have been trained in health related activities.
Those trained in HBMF are referred to as community drug
distributors (CDDs). As is the case for all CORPs, the work
of CDDs is meant to be voluntary, but facilitated though
incentives provided by the community and the MoH [19].
Malaria is endemic over most of Uganda, with varying lev-
els of endemicity. In the IDP population of Gulu district,
malaria/fever is the main cause of death in children under
5 years, comprising an estimated 25.3% of self-reported
mortality [21]. Aggregated annual data on outpatient
attendance collected through the health management
information system (HMIS) also indicates that malaria
poses a considerable burden on this district. Treatment for
malaria constitutes about 45% of all outpatient attend-
ance; in children below the age of five years this figure
reaches approximately 60% (Office of the District Direc-
tor of Health Services, Gulu; unpublished data).Malaria Journal 2006, 5:40 http://www.malariajournal.com/content/5/1/40
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Antimalarial medication and distribution
The HBMF strategy relies on the use of a pre-packaged
anti-malarial treatment, called HOMAPAK®. Each treat-
ment course consists of one tablet of sulfadoxine-
pyrimethamine (SP) and three tablets of chloroquine
(CQ), delivered in a blister pack and to be taken over three
consecutive days (SP + CQ on day 1). For ease of use, the
blister pack has been labelled 'Day 1, Day 2, Day 3' and
has a perforation between the doses for each of the days
(figure 1). To provide the right dose for weight,
HOMAPAK® has been made available in two different
packs with different doses per tablet, one for children age
two months to 23 months (red package) and one for chil-
dren age 24 to 59 months (green package). The outside of
the packages and the blister packs are labelled with a dos-
ing schedule in English, and a leaflet inside the package
provides detailed instructions in English, Kiswahili, Ateso,
Luganda, Luo and Runyakitara. It is manufactured by
Kampala Pharmaceutical Industries (1996) Ltd., P.O. Box
7551, Kampala, Uganda.
HOMAPAK® is distributed free of charge at community
level through the public health system. In the IDP camps,
the stock is kept at the health units and issued to CDDs
when required. To monitor distribution, CDDs have been
issued with a patient register book. The records are meant
to be compiled on a monthly basis at the nearest health
units and to be forwarded to the office of the district direc-
tor of health services (DDHS).
Inclusion criteria
All caretakers listed in the CDDs' registers as having
received HOMAPAK® for their child, more than 3 days but
less than one week ago, were included in the study. The
one-week window was meant to ensure that the treatment
had only recently been completed and that the respond-
ent was still able to recall the details of seeking treatment
for this episode of her/his child's illness. It was also meant
to increase the chances that the blister pack had not been
disposed off and could be inspected by the surveyor, to
verify whether all of the tablets had been taken.
Sampling
Selection of camps was based on accessibility within one
day and on security considerations. LRA activity in the dis-
trict is still considerable and makes certain camps inacces-
sible, whereas travel to others is only possible with an
armed escort. Eight camps were selected and visited on
separate days (Table 1). At the time of the survey, all the
selected camps were accessible without an armed escort.
At least one day before the survey of a camp, the district
radio station broadcasted a message to inform the camp
leader, health staff and the CDDs of the survey, to request
their presence at the health units at 10 a.m. and to ask any
caretakers that had obtained HOMAPAK® during the last
week to stay at home during the morning. Most camp
inhabitants regularly listen to the radio and this method
is commonly used to convey messages in this remote area.
On arrival in each camp, the four surveyors and the study
investigator were introduced and the purpose of the study
was outlined. Together with each CDD, his/her registers
were screened for last month's activities. As the register
has no column to record the date, surveyors together with
the CDDs worked their way backwards through the regis-
ter to establish which patients met the inclusion criteria.
The CDD and one surveyor then visited each of these
households. If the caretaker or a suitable respondent was
present and if these agreed to participate in the study an
interview was conducted. If the HOMAPAK® blister pack
had been retained by the household it was inspected for
remaining tablets. If no suitable respondent was present
in a household the next one in the register was visited.
After visiting all potential study participants from one reg-
ister, the surveyor returned to the health units and
repeated the process with another CDD. This process was
continued until all the registers of the CDDs that had
come to meet the survey team had been screened.
Data collection
A four page (26 questions) semi-structured questionnaire
was developed in English. It was designed to cover aspects
of adherence, treatment seeking, packaging and malaria
related knowledge. For consistency, the Luo words for spe-
cific terms describing time of day or symptoms of illness
were agreed upon by the surveyors and included in the
questionnaire. Surveyors were trained on the use of the
questionnaire and requested to ask questions in an open
way. All surveyors spoke fluent English and Luo. Ques-
Examples of HOMAPAK® blister packs for children age 2 –  23 months (red package) and 24 – 59 months (green pack- age) Figure 1
Examples of HOMAPAK® blister packs for children age 2 – 
23 months (red package) and 24 – 59 months (green pack-
age).Malaria Journal 2006, 5:40 http://www.malariajournal.com/content/5/1/40
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tions were asked in Luo and responses recorded under the
appropriate sections of the questionnaire.
Prior to each interview, the surveyors introduced them-
selves and the study, based on a pre-formulated introduc-
tion, and asked caretakers for their consent. To determine
whether a CDD had provided the correct dose of
HOMAPAK®, his/her record of the age of the child and the
colour of the pack distributed (red or green) were com-
pared. For children with a recorded age of 2 years, both
red and green HOMAPAK® were considered as correct, as
it was impossible to determine the exact age of the child.
Caretakers rarely have birth certificates for their children
and it must thus be assumed that they give an approxi-
mate age when they report to the CDD.
Apart from administering the questionnaire and inspect-
ing the blister pack, no other methods for measuring drug
usage and adherence (e.g. blood and urine assays) were
employed, due to logistic and funding limitations. A
number of studies have shown that carer-reported drug
histories can be reliable [23-25], though results of other
investigators did not confirm this [26]. For verification,
inspection of blister packs was chosen, where possible.
Definition of adherence
Children whose caretakers showed a blister pack that still
contained drugs at the time of the home visit were consid-
ered non-adherent, if the questionnaire confirmed that
treatment had been received more than 3 days ago and
should, therefore, have been completed. In cases where
the caretaker presented an empty blister pack and stated
that all medication had been used to treat the same child,
or where no blister pack was presented and the caretaker
stated that the course had been completed, the patient was
considered compliant.
Data analysis
Questionnaires were checked for completeness and con-
sistency at the end of each field day. For some questions
an open option had been included to record the respond-
ent's answer if it did not fit into the pre-determined cate-
gories. These answers were screened and coded into as
many additional categories as seemed appropriate. The
data were then entered into the study database in Micro-
soft Excel. Once the study had been completed, the data
file was checked for completeness before exporting it to
STATA 9.0 (Stata Corp., USA 2005). Further checks on the
completeness of the data were performed in STATA 9.0
prior to analysis. Sample characteristics and patient's clas-
sification were described as proportions and, where
deemed appropriate, presented with 95% confidence
intervals (CI). Variations between the camps were not
investigated, as this had not been part of the data analysis
plan. Numbers of observations were also too small for
some of the camps to allow meaningful stratified analysis.
Results
Summary of study population
From 12 to 19 September 2005, 243 caretakers were
approached in eight IDP camps, none of whom refused to
take part in the study. Of these, 226 (93%) were mothers,
six (2.5%) were fathers, five (2.1%) were grandmothers
and the remainder were other relatives. Two of the moth-
ers were found to be still treating their children, because
they were visited less than three days after obtaining treat-
ment. They were excluded from further analysis. The
mean age of children that had been treated with
HOMAPAK® was 2.5 years (95% CI: 2.4 – 2.7).
HOMAPAK® dosage and adherence
95.9% of children (CI: 93.3% – 98.4%) received the cor-
rect dose of HOMAPAK® for their age (Table 2). Though
we did not systematically investigate reasons for provid-
ing the wrong dose, discussion with CDDs provided evi-
dence that, at least in some cases, they had run out of the
correct packages.
Out of all the caretakers interviewed, 126 (52.3%) had
retained the blister pack. Adherence in this group was
92.9%, whereas adherence reported by caretakers that had
not retained the blister pack was 100%. Overall adherence
Table 1: List of camps surveyed and their characteristics
Name of Camp Sub-District Distance from 
Gulu Town 
(km)
Population Households HOMAPAK 
Drug 
Distributors
Health Units
Unyama Aswa 11 11,221 3,064 20 √
Teyapadhola Aswa 32 5,395 1,445 11 √
Paicho Aswa 24 7,968 2,142 17 √
Awer Kilak 20 14,293 3,247 22 √
Lacor Kilak 14 5,371 1,345 2 ×
Pabbo Kilak 40 40,870 9,396 58 √
Palenga Omoro 16 8,859 1,971 13 √
Pagak Kilak 24 6,694 2,150 18 ×Malaria Journal 2006, 5:40 http://www.malariajournal.com/content/5/1/40
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was thus 96.3% (CI: 93.9% – 98.7%), assuming correct
reporting by caretakers (Table 2). Of the nine caretakers
who had not completed the course for their child, four
stated that they had stopped because the child got better,
three forgot to administer the treatment, one had stopped
because the child had vomited and one because the child
did not like the taste of the tablets.
Treatment seeking behaviour and effects of treatment
Caretaker's reports of seeking treatment within 24 hours
did not always match the records of the CDDs. In 208
(86.3%) cases, the CDD's records on treatment seeking
were consistent with the statement provided by the care-
takers, who overall reported that 85.5% would seek treat-
ment within 24 hours (Table 3).
Of the 35 (14.5%) caretakers who delayed seeking treat-
ment for their child, it was most common to state that
they either had medicines at home (25.7%) or that they
had thought the illness would resolve itself (25.7%). The
third most common reply was that the CDD had not been
available at the time (20.0%). Other responses were that
they had no time (8.6%), had bought other medicine first
(8.6%) or were away from home when the child got sick
(5.7%).
As part of their reporting, CDDs should register the out-
come of HOMAPAK® treatment and whether any adverse
reactions occurred. To complete these two columns, fol-
low-up of the patient is required. Inspections of the regis-
ters showed that this had often not been done. For 50
(20.8%) and 61 (25.3%) of patients the respective col-
umns for outcome or adverse reaction had not been com-
pleted. For the cases where records were available, these
showed that 14 (5.8%) patients had been referred by the
CDD and that 177 (92.7%) children had recovered (Table
3).
Adverse reactions seemed the most problematic to record,
as CDDs were often unclear of the definition or how to
record it (the options are "yes/no", but seem to have been
confused in some cases where all patients had been
recorded as having suffered from adverse reactions). The
data in Table 3 were compiled after seeking some clarifi-
cation from the CDDs, but still have to be interpreted with
caution, particularly as the majority of adverse reactions
were reported from one camp (Paicho). However, overall
it seems as thought the CQ + SP combination causes few
side effects in young children.
Use of printed treatment information and perception of 
blister pack
Use of the dosage chart and other treatment information
printed on the pack and on the leaflet inside the pack was
limited, largely because most caretakers (87.8%) could
not read. 36 (14.9%) respondents stated that they had
read the information on the pack and only 20 (8.3%) that
they had read the inserted leaflet (Table 4). Apart from
being unable to read, people did not consult the leaflet
because of the small writing, lack of time or because the
text was perceived as being too complicated. Of those that
stated that they had read the information on the pack, all
found it useful. Similarly, 90% of the few respondents
that had read the inserted leaflet reported that they found
it useful.
Though only a small proportion of caretakers made use of
the information material provided with HOMAPAK®, it
was found that 47.0% of the respondents that had not
read any of the information had been told by the CDD
how to administer the drug. An additional three respond-
ents stated that they already knew how to use
HOMAPAK®. Whether all other caretakers used the medi-
cation without having obtained instructions cannot be
judged from the present data. Observation during inter-
views seemed to suggest that caretakers were familiar with
Table 2: Proportion of children that received the correct treatment dose and adherence of their caretakers to the treatment regimen
Name of Camp Correct Package of 
HOMAPAK® Received (%)
Blister Pack Retained (%) Overall Adherence of 
Caretakers (%)*
Unyama 27 (100) 19 (70.4) 24 (88.9)
Teyapadhola 19 (90.5) 17 (81.0) 20 (95.3)
Paicho 37 (94.9) 22 (56.4) 36 (92.3)
Awer 18 (100) 8 (44.4) 17 (94.4)
Lacor 8 (80.0) 5 (50.0) 10 (100)
Pabbo 59 (96.7) 16 (26.2) 61(100)
Palenga 19 (90.5) 11 (52.4) 20 (95.2)
Pagak 44 (100) 28 (63.6) 44 (100)
Total 231 (95.9) 126 (52.3) 232 (96.3)
* Combined data from caretakers that had retained the blister pack and those that had not, but reported to have used all the drugs to treat the 
same childMalaria Journal 2006, 5:40 http://www.malariajournal.com/content/5/1/40
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its use. To clarify what role the CDDs play in educating
caretakers and whether caretakers obtain treatment infor-
mation through other channels (e.g. neighbours), future
investigations should include a question on this aspect.
When asked whether the blister packing itself was per-
ceived as being useful, all respondents apart from one
who was undecided replied that they approved of the
pack. The majority (92.5%) mentioned that they like the
blister packaging because it keeps the drugs clean and/or
dry. Other frequently quoted reasons were that it makes
the drugs easier to use (32.9%) and provides an exact dos-
age (28.8%). A few respondents stated that it helps them
to report to the CDD or the health units what type of med-
ication their child has received in the past (1.3%), that it
kept the drugs safe (2.5%) or that they like it because it
has instructions on it (2.1%).
Knowledge of signs and symptoms of malaria, and 
response to signs of fever
Investigation into the awareness of malaria symptoms
showed that 95.4% of caretakers associated fever with
malaria. However, many other less specific symptoms,
such as diarrhoea, vomiting or feeling dizzy, were also fre-
quently mentioned. As a first response to fever, caretakers
said they mainly use what they referred to as 'tepid spong-
ing' (58.1%) or go to see the CDD (39.4%). In discussion
it emerged that respondents actually wash their child with
cold water rather than use 'tepid sponging'.
Generally, action is taken either immediately (56.0%) or
after a few hours (37.3%). When the condition of the
child does not improve, many caretakers said that they
again consult with the CDD (52.7%) to get further advice
or be referred to hospital. Others stated that they would go
directly to the health units (36.9%) or to the hospital
(10.4%).
Discussion
The present study shows that CDDs play an important
role in the control of malaria in IDP camps, some of them
providing presumptive malaria treatment for febrile ill-
ness to more than 60 children per month. Many are highly
motivated despite limited or no support or incentives
(most CDDs were not regularly supervised and had
received only one bar of soap in the last two years). Some
even took the initiative to improve on the HOMAPAK®
register by adding columns to record the date and name of
the caretaker. Despite the overall positive impression of
the current implementation of HBMF, the visit of the sur-
vey team was often seen as an occasion for the CDDs to
request more support. Promises that had been made dur-
ing their training have clearly not been met. This observa-
tion is consistent with that of other studies [19], who
highlighted the need for further technical support and for
delivery of promised incentives.
Fortunately, even in the absence of basic support, HBMF
was working well. Most caretakers sought advice within
24 hours of their children falling ill with fever, were pro-
vided with the correct treatment and adhered to it. The bit-
ter taste of the chloroquine tablets did not seem to affect
adherence. Only one of the mothers reported that the
treatment was not completed because her child had not
liked the taste. In any case, sugar-coating of tablets would
only hide the bitter taste when tablets are administered
whole, but some mothers said that they crush the tables
before giving it to their babies or young children. By far
the most important reasons for not adhering were that
caretakers had observed that their child had recovered or
that they had forgotten to give the drug (which may have
been due to the fact that the child had got better). This
shows that it is necessary to encourage caretakers to com-
plete the treatment course, which may be achieved by
making them and CDDs more aware of the risks of non-
Table 3: Treatment seeking behaviour and effects of treatment
Name of Camp Treatment Seeking Within 24 
Hours (%)*
Recovered After Treatment 
(%)**
No Adverse Reaction to 
Treatment (%)**
Unyama 21 (77.8) 23 (95.8) 23 (95.8)
Teyapadhola 21 (100) 16 (100) 16 (100)
Paicho 32 (82.1) 27 (87.1) 22 (78.6)
Awer 17 (94.4) 14 (100) 16 (100)
Lacor 9 (90.0) 10 (100) 10 (100)
Pabbo 50 (82.0) 34 (85.0) 33 (100)
Palenga 17 (81.0) 17 (89.5) 17 (100)
Pagak 39 (89) 36 (97.3) 36 (100)
Total 206 (85.5) 177 (92.7) 173 (96.1)
* As stated by the caretaker (data from CDD register not shown)
** Proportions in this column are based on available records for this category.Malaria Journal 2006, 5:40 http://www.malariajournal.com/content/5/1/40
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adherence (i.e. therapeutic failure and selection for drug
resistance).
As far as could be judged from the registers and observa-
tions, most patients had recovered and few had experi-
enced any adverse effect. Unfortunately, recording of data
on these latter aspects was often incomplete, because
patients had not been followed-up and/or because CDDs
were unclear as to the exact definition of an adverse reac-
tion. The observed lack of attention to patient follow-up
and reporting could be resolved through regular supervi-
sion, feedback and refresher training. Prior to the planned
introduction of a new combination therapy, it would
therefore be useful to revise the exiting register, to include
columns for the date and for the name of the head of
household. Introduction of the amended register could
then be used to provide refresher training on reporting,
health education, etc. and to clearly define adverse reac-
tions.
Though the observed and reported adherence of caretak-
ers to HOMAPAK®  was reassuring, there is room for
improvement on knowledge and practices related to
malaria. Many caretakers clearly associated fever with
malaria, but also did so with a large number of other signs
and symptoms. In the absence of fever, these may not
indicate infection with Plasmodium spp., but may be the
result of another, equally dangerous, childhood disease.
For HBMF, it is important to continue health education
on the importance of fever, its diagnosis and the need to
seek prompt treatment. To avoid confusion of caretakers
(and CDDs) it will be important to ensure that these mes-
sages are kept simple and are consistent with those deliv-
ered through other programmes.
Further education will also be required on the use of tepid
sponging. As a first response to febrile illness many wash
their child with cold water, which may worsen rather than
improve the fever. Educational materials should be devel-
oped to outline simple methods of tepid sponging, partic-
ularly on how to raise the water temperature on a cool
night (e.g. by putting a damp cloth on the caretaker's body
before sponging the child). Education should be targeted
at caretakers and CDDs, as the latter are an important
source of information particularly for illiterate people. An
option may be to provide CDDs with illustrated flip-
charts to help them to better relay information to the care-
takers.
None of the caretakers stated that they used traditional
healers, either as an immediate source of treatment when
their child has fever or if the child does not improve.
However, discussions with the surveyors at the end of
each survey day showed that they had noticed that some
of the children had small incisions on their chest or other
signs that traditional healers had been consulted during
the child's life. The present survey tool and method were
not suitable to investigate the role of traditional healers in
the IDP camps. More research on this subject is encour-
aged, to establish whether traditional healers are con-
sulted in the treatment of febrile illness in the IDP camps,
whether they may contribute to delays in consulting
CDDs and if they can be brought into the HBMF strategy.
Previous work in western Uganda indicates that local ill-
ness categorisation may exclude some fevers from being
treated with 'western' treatment [27]. This may result in
delayed and under-treatment of potential malaria.
The results on the acceptability of the blister-pack are con-
sistent with results from a study in western Uganda prior
to the introduction of HOMAPAK®  [28]. The authors
found that 90.5% of women preferred pre-packed treat-
ment over loosely packed tablets. The most mentioned
reasons for this preference were safety and cleanliness. As
in the present study, it was observed that few respondents
mentioned correct dosing as an important aspect of pre-
packaged drugs. With reference to results from a study by
the same first author [29], which showed that more than
81% of rural mothers knew the correct dose of CQ treat-
ment for an adult, and 37% knew it for a 3 year old child,
it was suggested that a high proportion of caretakers are
confident about dosing but find cleanliness more impor-
Table 4: Caretakers use of printed information
Name of Camp Read Information On Pack (%) Read Information Inside Pack (%)
Unyama 6 (22.2) 4 (14.8)
Teyapadhola 6 (28.6) 4 (19.1)
Paicho 4 (10.3) 1 (2.6)
Awer 3 (16.7) 2 (11.1)
Lacor 3 (30.0) 0
Pabbo 7 (11.5) 3 (4.9)
Palenga 1 (4.8) 1 (4.8)
Pagak 6 (13.6) 65 (11.4)
Total 36 (14.9) 20 (8.3)Malaria Journal 2006, 5:40 http://www.malariajournal.com/content/5/1/40
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tant. Whether caretakers in the IDP population are aware
of correct CQ + SP dosages for their children was not
investigated, but the conclusion that pre-packaged drugs
are clearly acceptable [28] certainly also applies to the IDP
population. The main reason for this seems to be cleanli-
ness and it may be worthwhile to highlight other positive
aspects in future education campaigns. The use of pre-
packaging to guide dosing will certainly become more
important and useful when new drug regimens (e.g.
ACTs) with more tablets and more frequent doses, are
introduced.
Methodological considerations of importance in inter-
preting results from the present study are its generalizabil-
ity and potential biases. For the following reasons the
results may not apply to other rural areas of Uganda that
are unaffected by conflict. In IDP camps people live closer
together than in rural villages, which reduces travel to
reach a CDD. In areas not affected by the chronic emer-
gency, caretakers may take longer to seek treatment, CDDs
may spend more time away due to better security and
employment opportunities, and follow-up of patients
may be even lower than in IDP camps. Fewer caretakers
may also seek treatment from CDDs because they have
more alternatives, such as private practitioners, drug
shops or traditional healers.
The camps sampled were all relatively close to the town of
Gulu, in areas that have comparatively good security. In
camps that are located in areas that were not accessible to
the survey team or that could not have been reached and
surveyed within one day, the implementation of the
HBMF strategy may be weaker. However, even within the
easily reachable camps we observed that drug supply and
implementation was not always as good as might be
expected, mainly because the persons in charge of the
health units did not feel sufficiently responsible to facili-
tate the work of the CDDs and to ensure a constant
HOMAPAK® supply. Based on our limited observations,
the success of HBMF is largely dependent on the motiva-
tion of staff in charge of the local health units and on the
CDDs, but not on distance from the district centre.
The survey relied heavily on the cooperation of CDDs to
identify and find caretakers. At least 60% of the CDDs
came to meet the survey team at the health units and were
extremely motivated and cooperative. However, some
failed to come because they had to attend to other duties
and others just did not show-up. The latter may not have
heard the announcement on the radio. As it was also
noticed, some individuals that came to meet the survey
team were less motivated than others. They were generally
not seeing many patients, had limited interaction with the
ones they saw and were not completing their registers
with care. Also, despite a request for caretakers to remain
home during the morning, many had left to attend to
their fields and were not available for an interview. All of
the above factors may have introduced bias, potentially
towards better adherence than may have been observed if
camps had been selected at random and been revisited
until all caretakers had been interviewed.
Conclusion
In IDP camps the HBMF strategy forms an important com-
ponent of medical care for young children. In case of
febrile illness, most caretakers obtain prompt and ade-
quate antimalarial treatment, and adhere to it. It is
expected that a large proportion of malaria episodes are
thus treated before complications can arise. Implementa-
tion of the strategy now needs to focus on improving
monitoring, supervision and general support to CDDs
and by targeting them and caretakers with educational
messages. There is a need to realize that heavy reliance on
community volunteers does not make HBMF self-sustain-
ing and that its future success depends on ongoing com-
mitment from the MoH and international donors.
Discussions on a suitable replacement combination for
HBMF are well advanced, and have raised new questions
about adherence. Further operational research will be
required to establish how more complicated treatment
regimens can best be delivered by CDDs.
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